Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability

Neuroscience

Volumn 228, Issue , 2013, Pages 73-82

  Chou, V P ^a   Holman, T R ^b   Manning Bog, A B ^a  

^a SRI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dopamine; Inflammation; Lipoxygenase; MPTP; Nigrostriatal; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; SODIUM CHLORIDE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CELL ACTIVATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME DEFICIENCY; FEMALE; GENOTYPE; IMMUNOREACTIVITY; MALE; MICROGLIA; MOUSE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRIATONIGRAL DEGENERATION; TRANSGENIC MOUSE; WESTERN BLOTTING; WILD TYPE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; ARACHIDONATE 5-LIPOXYGENASE; CORPUS STRIATUM; DOPAMINE; ISOENZYMES; LIPOXYGENASES; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; SUBSTANTIA NIGRA;

EID: 84868577749     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.10.009     Document Type: Article

References (101)

1. Adibhatla R.M., Hatcher J.F. Altered lipid metabolism in brain injury and disorders. Subcell Biochem 2008, 49:241-268.
2. Badr K.F. Glomerulonephritis: roles for lipoxygenase pathways in pathophysiology and therapy. Curr Opin Nephrol Hypertens 1997, 6:111-118.
3. Basselin M., Kim H.W., Chen M., Ma K., Rapoport S.I., Murphy R.C., Farias S.E. Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation. J Lipid Res 2010, 51:1049-1056.
4. Bendani M.K., Palluy O., Cook-Moreau J., Beneytout J.L., Rigaud M., Vallat J.M. Localization of 12-lipoxygenase mRNA in cultured oligodendrocytes and astrocytes by in situ reverse transcriptase and polymerase chain reaction. Neurosci Lett 1995, 189:159-162.
5. Brash A.R. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem 1999, 274:23679-23682.
6. Breydo L., Wu J.W., Uversky V.N. Alpha-synuclein misfolding and Parkinson's disease. Biochim Biophys Acta 2012, 1822:261-285.
7. Canals S., Casarejos M.J., de Bernardo S., Rodriguez-Martin E., Mena M.A. Nitric oxide triggers the toxicity due to glutathione depletion in midbrain cultures through 12-lipoxygenase. J Biol Chem 2003, 278:21542-21549.
8. Carta A.R., Frau L., Pisanu A., Wardas J., Spiga S., Carboni E. Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience 2011, 194:250-261.
9. Chen H., Manev H. Effects of minocycline on cocaine sensitization and phosphorylation of GluR1 receptors in 5-lipoxygenase deficient mice. Neuropharmacology 2011, 60:1058-1063.
10. Cheng Y., He G., Mu X., Zhang T., Li X., Hu J., Xu B., Du G. Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical profile. Neurosci Lett 2008, 441:16-20.
11. Chu J., Giannopoulos P.F., Ceballos-Diaz C., Golde T.E., Pratico D. Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice. Mol Neurodegener 2012, 7:1-10.
12. Chu J., Pratico D. Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of gamma-secretase. Am J Pathol 2011, 178:1762-1769.
13. Chu J., Zhuo J.M., Pratico D. Transcriptional regulation of beta-secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments. Ann Neurol 2012, 71:57-67.
14. Cui L., Zhang X., Yang R., Liu L., Wang L., Li M., Du W. Baicalein is neuroprotective in rat MCAO model: role of 12/15-lipoxygenase, mitogen-activated protein kinase and cytosolic phospholipase A2. Pharmacol Biochem Behav 2010, 96:469-475.
15. Davidson B.C. Eicosanoid precursor polyenoic fatty acids modulate synaptic levels of dopamine in ex-vivo slices of rat brain striatum. In Vivo 2003, 17:83-88.
16. de Bernardo S., Canals S., Casarejos M.J., Solano R.M., Menendez J., Mena M.A. Role of extracellular signal-regulated protein kinase in neuronal cell death induced by glutathione depletion in neuron/glia mesencephalic cultures. J Neurochem 2004, 91:667-682.
17. Dobrian A.D., Lieb D.C., Cole B.K., Taylor-Fishwick D.A., Chakrabarti S.K., Nadler J.L. Functional and pathological roles of the 12- and 15-lipoxygenases. Prog Lipid Res 2011, 50:115-131.
18. Farooqui A.A., Horrocks L.A. Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. Neuroscientist 2006, 12:245-260.
19. Farooqui A.A., Horrocks L.A., Farooqui T. Interactions between neural membrane glycerophospholipid and sphingolipid mediators: a recipe for neural cell survival or suicide. J Neurosci Res 2007, 85:1834-1850.
20. Firuzi O., Zhuo J., Chinnici C.M., Wisniewski T., Pratico D. 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J 2008, 22:1169-1178.
21. Fujisawa H., Okuno S. Regulation of the activity of tyrosine hydroxylase in the central nervous system. Adv Enzyme Regul 1989, 28:93-110.
22. Funk C.D., Cyrus T. 12/15-lipoxygenase, oxidative modification of LDL and atherogenesis. Trends Cardiovasc Med 2001, 11:116-124.
23. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978, 14:633-643.
24. Gubitosi-Klug R.A., Talahalli R., Du Y., Nadler J.L., Kern T.S. 5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy. Diabetes 2008, 57:1387-1393.
25. Gupta A., Kumar A., Kulkarni S.K. Licofelone attenuates MPTP-induced neuronal toxicity: behavioral, biochemical and cellular evidence. Inflammopharmacology 2010, 18:223-232.
26. Hashimoto K. Can minocycline prevent the onset of Alzheimer's disease?. Ann Neurol 2011, 69:739. author reply 739-740.
27. Hunot S., Hirsch E.C. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003, 53(Suppl. 3):S49-S58. discussion S58-S60.
28. Ikonomovic M.D., Abrahamson E.E., Uz T., Manev H., Dekosky S.T. Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J Histochem Cytochem 2008, 56:1065-1073.
29. Imai Y., Lu B. Mitochondrial dynamics and mitophagy in Parkinson's disease: disordered cellular power plant becomes a big deal in a major movement disorder. Curr Opin Neurobiol 2011, 21:935-941.
30. Imbesi M., Uz T., Manev R., Sharma R.P., Manev H. Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors. Neurosci Lett 2008, 447:134-137.
31. Jin G., Arai K., Murata Y., Wang S., Stins M.F., Lo E.H., van Leyen K. Protecting against cerebrovascular injury: contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia. Stroke 2008, 39:2538-2543.
32. Kettenmann H., Hanisch U.K., Noda M., Verkhratsky A. Physiology of microglia. Physiol Rev 2011, 91:461-553.
33. Kilpatrick I.C., Jones M.W., Phillipson O.T. A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J Neurochem 1986, 46:1865-1876.
34. Klegeris A., McGeer P.L. Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging 2002, 23:787-794.
35. Kramer B.C., Yabut J.A., Cheong J., Jnobaptiste R., Robakis T., Olanow C.W., Mytilineou C. Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites. Eur J Neurosci 2004, 19:280-286.
36. Kuhn H., O'Donnell V.B. Inflammation and immune regulation by 12/15-lipoxygenases. Prog Lipid Res 2006, 45:334-356.
37. Kurtuncu M., Battista N., Uz T., D'Agostino A., Dimitrijevic N., Pasquariello N., Manev R., Maccarrone M., Manev H. Effects of cocaine in 5-lipoxygenase-deficient mice. J Neural Transm 2008, 115:389-395.
38. Li Y., Maher P., Schubert D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 1997, 19:453-463.
39. Limor R., Sharon O., Knoll E., Many A., Weisinger G., Stern N. Lipoxygenase-derived metabolites are regulators of peroxisome proliferator-activated receptor gamma-2 expression in human vascular smooth muscle cells. Am J Hypertens 2008, 21:219-223.
40. Listi F., Caruso C., Lio D., Colonna-Romano G., Chiappelli M., Licastro F., Candore G. Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from northern Italy: implication for pharmacogenomics. J Alzheimers Dis 2010, 19:551-557.
41. Liu C., Xu D., Liu L., Schain F., Brunnstrom A., Bjorkholm M., Claesson H.E., Sjoberg J. 15-Lipoxygenase-1 induces expression and release of chemokines in cultured human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009, 297:L196-L203.
42. Lopez-Parra M., Claria J., Titos E., Planaguma A., Parrizas M., Masferrer J.L., Jimenez W., Arroyo V., Rivera F., Rodes J. The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin. J Hepatol 2005, 42:75-81.
43. Manev H. 5-Lipoxygenase gene polymorphism and onset of Alzheimer's disease. Med Hypotheses 2000, 54:75-76.
44. Manev H., Chen H., Dzitoyeva S., Manev R. Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:315-319.
45. Manev H., Manev R. 5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease. Med Hypotheses 2006, 66:501-503.
46. Manev H., Uz T., Manev R., Zhang Z. Neurogenesis and neuroprotection in the adult brain. A putative role for 5-lipoxygenase?. Ann N Y Acad Sci 2001, 939:45-51.
47. Manev H., Uz T., Qu T. 5-Lipoxygenase and cyclooxygenase mRNA expression in rat hippocampus: early response to glutamate receptor activation by kainate. Exp Gerontol 2000, 35:1201-1209.
48. Manev H., Uz T., Sugaya K., Qu T. Putative role of neuronal 5-lipoxygenase in an aging brain. FASEB J 2000, 14:1464-1469.
49. Manning-Bog A.B., Caudle W.M., Perez X.A., Reaney S.H., Paletzki R., Isla M.Z., Chou V.P., McCormack A.L., Miller G.W., Langston J.W., Gerfen C.R., Dimonte D.A. Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol Dis 2007, 27:141-150.
50. Manning-Bog A.B., McCormack A.L., Purisai M.G., Bolin L.M., Di Monte D.A. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 2003, 23:3095-3099.
51. Marks F., Muller-Decker K., Furstenberger G. A causal relationship between unscheduled eicosanoid signaling and tumor development: cancer chemoprevention by inhibitors of arachidonic acid metabolism. Toxicology 2000, 153:11-26.
52. McCoy M.K., Cookson M.R. Mitochondrial quality control and dynamics in Parkinson's disease. Antioxid Redox Signal 2012, 16:869-882.
53. Menna C., Olivieri F., Catalano A., Procopio A. Lipoxygenase inhibitors for cancer prevention: promises and risks. Curr Pharm Des 2010, 16:725-733.
54. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004, 63:901-910.
55. Mosca L., Foppoli C., Coccia R., Rosei M.A. Pheomelanin production by the lipoxygenase-catalyzed oxidation of 5-S-cysteinyldopa and 5-S-cysteinyldopamine. Pigment Cell Res 1996, 9:117-125.
56. Mytilineou C., Kokotos Leonardi E.T., Kramer B.C., Jamindar T., Olanow C.W. Glial cells mediate toxicity in glutathione-depleted mesencephalic cultures. J Neurochem 1999, 73:112-119.
57. Mytilineou C., Kramer B.C., Yabut J.A. Glutathione depletion and oxidative stress. Parkinsonism Relat Disord 2002, 8:385-387.
58. Neilson A.P., Ren J., Hong Y.H., Sen A., Smith W.L., Brenner D.E., Djuric Z. Effect of fish oil on levels of R- and S-enantiomers of 5-, 12-, and 15-hydroxyeicosatetraenoic acids in mouse colonic mucosa. Nutr Cancer 2012, 64:163-172.
59. Ogawa N., Tanaka K., Asanuma M. Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum. Neurochem Res 2000, 25:755-758.
60. Ouchi Y., Yagi S., Yokokura M., Sakamoto M. Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord 2009, 15(Suppl. 3):S200-S204.
61. Parkinson J.F. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm Allergy Drug Targets 2006, 5:91-106.
62. Phillis J.W., Horrocks L.A., Farooqui A.A. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev 2006, 52:201-243.
63. Piomelli D., Wang J.K., Sihra T.S., Nairn A.C., Czernik A.J., Greengard P. Inhibition of Ca2+/calmodulin-dependent protein kinase II by arachidonic acid and its metabolites. Proc Natl Acad Sci U S A 1989, 86:8550-8554.
64. Planaguma A., Kazani S., Marigowda G., Haworth O., Mariani T.J., Israel E., Bleecker E.R., Curran-Everett D., Erzurum S.C., Calhoun W.J., Castro M., Chung K.F., Gaston B., Jarjour N.N., Busse W.W., Wenzel S.E., Levy B.D. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008, 178:574-582.
65. Planaguma A., Titos E., Lopez-Parra M., Gaya J., Pueyo G., Arroyo V., Claria J. Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4. FASEB J 2002, 16:1937-1939.
66. Plowey E.D., Chu C.T. Synaptic dysfunction in genetic models of Parkinson's disease: a role for autophagy?. Neurobiol Dis 2011, 43:60-67.
67. Prasad V.V., Nithipatikom K., Harder D.R. Ceramide elevates 12-hydroxyeicosatetraenoic acid levels and upregulates 12-lipoxygenase in rat primary hippocampal cell cultures containing predominantly astrocytes. Neurochem Int 2008, 53:220-229.
68. Pratico D., Zhukareva V., Yao Y., Uryu K., Funk C.D., Lawson J.A., Trojanowski J.Q., Lee V.M. 12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am J Pathol 2004, 164:1655-1662.
69. Puccio S., Chu J., Pratico D. Involvement of 5-lipoxygenase in the corticosteroid-dependent amyloid beta formation: in vitro and in vivo evidence. PLoS One 2011, 6:e15163.
70. Qu T., Uz T., Manev H. Inflammatory 5-LOX mRNA and protein are increased in brain of aging rats. Neurobiol Aging 2000, 21:647-652.
71. Rosei M.A., Blarzino C., Foppoli C., Mosca L., Coccia R. Lipoxygenase-catalyzed oxidation of catecholamines. Biochem Biophys Res Commun 1994, 200:344-350.
72. Roy P., Roy S.K., Mitra A., Kulkarni A.P. Superoxide generation by lipoxygenase in the presence of NADH and NADPH. Biochim Biophys Acta 1994, 1214:171-179.
73. Roy P., Sajan M.P., Kulkarni A.P. Lipoxygenase-mediated glutathione oxidation and superoxide generation. J Biochem Toxicol 1995, 10:111-120.
74. Schintu N., Frau L., Ibba M., Caboni P., Garau A., Carboni E., Carta A.R. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 2009, 29:954-963.
75. Scholz M., Ulbrich H.K., Dannhardt G. Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem 2008, 43:1152-1159.
76. Serhan C.N. Novel chemical mediators in the resolution of inflammation: resolvins and protectins. Anesthesiol Clin 2006, 24:341-364.
77. Serhan C.N., Samuelsson B. Lipoxins: a new series of eicosanoids (biosynthesis, stereochemistry, and biological activities). Adv Exp Med Biol 1988, 229:1-14.
78. Simonian N.A., Coyle J.T. Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996, 36:83-106.
79. Sobrado M., Pereira M.P., Ballesteros I., Hurtado O., Fernandez-Lopez D., Pradillo J.M., Caso J.R., Vivancos J., Nombela F., Serena J., Lizasoain I., Moro M.A. Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci 2009, 29:3875-3884.
80. St-Pierre J., Drori S., Uldry M., Silvaggi J.M., Rhee J., Jager S., Handschin C., Zheng K., Lin J., Yang W., Simon D.K., Bachoo R., Spiegelman B.M. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006, 127:397-408.
81. Stewart L.R., White A.R., Jobling M.F., Needham B.E., Maher F., Thyer J., Beyreuther K., Masters C.L., Collins S.J., Cappai R. Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126. J Neurosci Res 2001, 65:565-572.
82. Sugaya K., Uz T., Kumar V., Manev H. New anti-inflammatory treatment strategy in Alzheimer's disease. Jpn J Pharmacol 2000, 82:85-94.
83. Sulzer D., Bogulavsky J., Larsen K.E., Behr G., Karatekin E., Kleinman M.H., Turro N., Krantz D., Edwards R.H., Greene L.A., Zecca L. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci U S A 2000, 97:11869-11874.
84. Sun L., Yang L., Xu Y.W., Liang H., Han J., Zhao R.J., Cheng Y. Neuroprotection of hydroxysafflor yellow A in the transient focal ischemia: inhibition of protein oxidation/nitration, 12/15-lipoxygenase and blood-brain barrier disruption. Brain Res 2012, 1473:227-235.
85. Tansey M.G., Frank-Cannon T.C., McCoy M.K., Lee J.K., Martinez T.N., McAlpine F.E., Ruhn K.A., Tran T.A. Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy?. Front Biosci 2008, 13:709-717.
86. Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010, 37:510-518.
87. Tassoni D., Kaur G., Weisinger R.S., Sinclair A.J. The role of eicosanoids in the brain. Asia Pac J Clin Nutr 2008, 17(Suppl. 1):220-228.
88. Ton T.G., Heckbert S.R., Longstreth W.T., Rossing M.A., Kukull W.A., Franklin G.M., Swanson P.D., Smith-Weller T., Checkoway H. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 2006, 21:964-969.
89. Ton T.G., Jain S., Biggs M.L., Thacker E.L., Strotmeyer E.S., Boudreau R., Newman A.B., Longstreth W.T., Checkoway H. Markers of inflammation in prevalent and incident Parkinson's disease in the Cardiovascular Health Study. Parkinsonism Relat Disord 2012, 18:274-278.
90. Tu X.K., Yang W.Z., Wang C.H., Shi S.S., Zhang Y.L., Chen C.M., Yang Y.K., Jin C.D., Wen S. Zileuton reduces inflammatory reaction and brain damage following permanent cerebral ischemia in rats. Inflammation 2010, 33:344-352.
91. Uz T., Dwivedi Y., Qeli A., Peters-Golden M., Pandey G., Manev H. Glucocorticoid receptors are required for up-regulation of neuronal 5-lipoxygenase (5LOX) expression by dexamethasone. FASEB J 2001, 15:1792-1794.
92. Uz T., Manev R., Manev H. 5-Lipoxygenase is required for proliferation of immature cerebellar granule neurons in vitro. Eur J Pharmacol 2001, 418:15-22.
93. Uz T., Pesold C., Longone P., Manev H. Aging-associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. FASEB J 1998, 12:439-449.
94. van Leyen K., Arai K., Jin G., Kenyon V., Gerstner B., Rosenberg P.A., Holman T.R., Lo E.H. Novel lipoxygenase inhibitors as neuroprotective reagents. J Neurosci Res 2008, 86:904-909.
95. Wang Z.J., Liang C.L., Li G.M., Yu C.Y., Yin M. Neuroprotective effects of arachidonic acid against oxidative stress on rat hippocampal slices. Chem Biol Interact 2006, 163:207-217.
96. Weaver J.R., Holman T.R., Imai Y., Jadhav A., Kenyon V., Maloney D.J., Nadler J.L., Rai G., Simeonov A., Taylor-Fishwick D.A. Integration of pro-inflammatory cytokines, 12-lipoxygenase and NOX-1 in pancreatic islet beta cell dysfunction. Mol Cell Endocrinol 2012, 358:88-95.
97. Werz O. 5-Lipoxygenase: cellular biology and molecular pharmacology. Curr Drug Targets Inflamm Allergy 2002, 1:23-44.
98. Yang H., Zhuo J.M., Chu J., Chinnici C., Pratico D. Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase. Biol Psychiatry 2010, 68:922-929.
99. Yao Y., Clark C.M., Trojanowski J.Q., Lee V.M., Pratico D. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol 2005, 58:623-626.
100. Yeung J., Apopa P.L., Vesci J., Kenyon V., Rai G., Jadhav A., Simeonov A., Holman T.R., Maloney D.J., Boutaud O., Holinstat M. Protein kinase C regulation of 12-lipoxygenase-mediated human platelet activation. Mol Pharmacol 2012, 81:420-430.
101. Zaleska M.M., Wilson D.F. Lipid hydroperoxides inhibit reacylation of phospholipids in neuronal membranes. J Neurochem 1989, 52:255-260.